XyloCor Therapeutics develops gene therapies for cardiovascular diseases, focusing on treatments for refractory angina and coronary artery bypass graft surgery.

Corteria Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapies for unaddressed heart failure subpopulations, with a focus on multi-organ benefits targeting the kidneys, heart, and vessels.